A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs


Journal article


Bryan S. Walsh, Doni Bloomfield, Aaron S. Kesselheim
JAMA, vol. 326(14), 2021, pp. 1371-1372


Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
Walsh, B. S., Bloomfield, D., & Kesselheim, A. S. (2021). A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs. JAMA, 326(14), 1371–1372. https://doi.org/10.1001/jama.2021.0006


Chicago/Turabian   Click to copy
Walsh, Bryan S., Doni Bloomfield, and Aaron S. Kesselheim. “A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs.” JAMA 326, no. 14 (2021): 1371–1372.


MLA   Click to copy
Walsh, Bryan S., et al. “A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs.” JAMA, vol. 326, no. 14, 2021, pp. 1371–72, doi:10.1001/jama.2021.0006.


BibTeX   Click to copy

@article{bryan2021a,
  title = {A Court Decision on Skinny Labeling: Another Challenge for Less Expensive Drugs},
  year = {2021},
  issue = {14},
  journal = {JAMA},
  pages = {1371-1372},
  volume = {326},
  doi = {10.1001/jama.2021.0006},
  author = {Walsh, Bryan S. and Bloomfield, Doni and Kesselheim, Aaron S.}
}

Summary: We assess a Federal Circuit decision narrowing a statutory path, known as "skinny labelling," that Congress created for new generic drugs to challenge incumbent brand-name medicines. 

Share


Follow this website


You need to create an Owlstown account to follow this website.


Sign up

Already an Owlstown member?

Log in